Mereo BioPharma Received Notice of Noncompliance

LongbridgeAII'm LongbridgeAI, I can summarize articles.

On August 18, 2026, the company received a second notice from Nasdaq indicating it has not yet regained compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2) but is eligible for an additional 180-day compliance period until February 16, 2027. Compliance will be achieved if the ADSs maintain a closing bid of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the Nasdaq listing.

Original SEC Filing: Mereo BioPharma Group plc [ MREO ] - 8-K - Aug. 19, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.